Uy Ear
Stock Analyst at Mizuho
(2.88)
# 1,547
Out of 4,883 analysts
63
Total ratings
39.47%
Success rate
11.24%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Outperform | $85 → $40 | $18.20 | +119.84% | 6 | Jun 18, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $20 → $23 | $21.24 | +8.29% | 11 | May 19, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $21.19 | +301.13% | 2 | May 15, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $20 → $21 | $13.76 | +52.62% | 14 | Feb 26, 2025 | |
| QURE uniQure | Maintains: Neutral | $7 → $20 | $14.28 | +40.06% | 4 | Dec 19, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Neutral | $23 → $1 | $0.60 | +66.36% | 1 | Dec 5, 2024 | |
| ALKS Alkermes | Maintains: Outperform | $35 → $40 | $29.00 | +37.93% | 5 | Nov 13, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $18 → $16 | $9.08 | +76.21% | 2 | Jul 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $11.41 | +250.57% | 1 | May 24, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $9.23 | +149.32% | 3 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $116 → $140 | $129.40 | +8.19% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $155.56 | -74.29% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $1.60 | +525.00% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $0.93 | +223.83% | 2 | Mar 1, 2023 |
Sarepta Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $85 → $40
Current: $18.20
Upside: +119.84%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Neutral
Price Target: $20 → $23
Current: $21.24
Upside: +8.29%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $21.19
Upside: +301.13%
Arcutis Biotherapeutics
Feb 26, 2025
Maintains: Outperform
Price Target: $20 → $21
Current: $13.76
Upside: +52.62%
uniQure
Dec 19, 2024
Maintains: Neutral
Price Target: $7 → $20
Current: $14.28
Upside: +40.06%
Relmada Therapeutics
Dec 5, 2024
Downgrades: Neutral
Price Target: $23 → $1
Current: $0.60
Upside: +66.36%
Alkermes
Nov 13, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $29.00
Upside: +37.93%
Sage Therapeutics
Jul 19, 2024
Maintains: Neutral
Price Target: $18 → $16
Current: $9.08
Upside: +76.21%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $11.41
Upside: +250.57%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $9.23
Upside: +149.32%
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $129.40
Upside: +8.19%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $155.56
Upside: -74.29%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $1.60
Upside: +525.00%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $0.93
Upside: +223.83%